Amphivena Therapeutics, Inc. is a privately held, clinical-stage, immuno-oncology company that is developing a novel platform of dual-action biologics that relieve immune suppression and drive T-cell activation and polarization to restore anti-cancer immunity in patients
The fundamental challenge in immuno-oncology is that a majority of patients do not respond to immunotherapies. Cancer patients exhibit tumor-induced immune suppression mediated by immune cell types such as myeloid derived suppressor cells (MDSC). T cell activating therapies can also trigger autoregulatory immune modulation, via MDSC recruitment.
Our proprietary platform is designed to potently and selectively deplete MDSC and to drive the activation and repolarization of T cells to relieve immune suppression and restore anti-cancer immunity in patients.
The AMPHIVENA ReSTORE™ platform provides dual-action biologics that relieve immune suppression and activate
T cell effector function in cancer patients
The platform can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing
Our lead candidate, AMV564, is currently in clinical studies in both solid tumor and hematologic cancers
We are advancing additional bivalent, multi-target candidates through preclinical development
November 9, 2020
South San Francisco, CA – November 9, 2020 — Today Amphivena presented updated clinical and translational data for the lead clinical candidate, AMV564, from the AMPHIVENA ReSTORETM (Relieve Suppression of T cells in Oncology and Reinvigorate Effectors) platform of bivalent T-cell engagers, in two poster presentations at the SITC 2020 Annual Meeting…
June 23, 2020
South San Francisco, CA – May 29, 2020 — AMV564, a novel first-in-class agent that depletes MDSC and polarizes T cells, is being investigated in Ph1 clinical trials in advanced solid tumors and hematological cancers and is well tolerated with single-agent activity across both solid and heme malignancies…
May 29, 2020
South San Francisco, CA – May 29, 2020 — Initial data from the Phase 1 dose escalation trial in 18 patients with advanced solid tumors shows AMV564 administered subcutaneously was well tolerated, with no dose-limiting toxicities…
November 9, 20202020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster Presentation (Clinical Update)